Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injec...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature [academic journals on nature.com]
2024
|
| _version_ | 1817932555945508864 |
|---|---|
| author | Borchert, GA Kiire, CA Stone, NM Akil, H Gkika, T Fischer, MD Xue, K Cehajic-Kapetanovic, J MacLaren, RE Charbel Issa, P Downes, SM De Silva, SR |
| author_facet | Borchert, GA Kiire, CA Stone, NM Akil, H Gkika, T Fischer, MD Xue, K Cehajic-Kapetanovic, J MacLaren, RE Charbel Issa, P Downes, SM De Silva, SR |
| author_sort | Borchert, GA |
| collection | OXFORD |
| description | Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Methods: Retrospective study at the Oxford Eye Hospital. Patients switched to faricimab from January to April 2023 with six months follow-up were identified via electronic medical records. Results: A total of 116 patients (151 eyes) were included. In 88 patients with nAMD (107 eyes), mean visual acuity remained stable: 62±17 ETDRS letters at baseline; 62±18 at six months (p > 0.05). Central subfield thickness (CST) reduced from 294 ± 73 μm to 270 ± 53 μm (p < 0.05) at six months. Subretinal or intraretinal fluid was present in 102 eyes (95%) at baseline and 75 eyes (70%) at follow-up (p < 0.05). Pigment epithelial detachment height decreased from 233 ± 134 μm to 188 ± 147 μm (p < 0.05). Mean treatment interval increased by 1.7 weeks (p < 0.05) and was extended in 61 eyes (57%) at six months. In 28 patients with DMO (44 eyes), visual acuity remained stable: 69 ± 15 letters at baseline; 70±15 at six months (p > 0.05). CST reduced from 355 ± 87 μm to 317 ± 82 μm (p < 0.05). Mean treatment interval increased by 1.4 weeks (p < 0.05) and was extended in 21 eyes (46%) by six months. Conclusions: Switching to faricimab in treatment resistant eyes led to improved anatomical response and extended treatment interval in a significant proportion of patients. Ongoing review of real-world data will inform longer-term outcomes of safety and effectiveness. |
| first_indexed | 2024-12-09T03:39:47Z |
| format | Journal article |
| id | oxford-uuid:c0660f21-0e4b-48a9-9e22-f85dcecb3c63 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:39:47Z |
| publishDate | 2024 |
| publisher | Springer Nature [academic journals on nature.com] |
| record_format | dspace |
| spelling | oxford-uuid:c0660f21-0e4b-48a9-9e22-f85dcecb3c632024-12-06T20:17:09ZReal-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedemaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c0660f21-0e4b-48a9-9e22-f85dcecb3c63EnglishJisc Publications RouterSpringer Nature [academic journals on nature.com]2024Borchert, GAKiire, CAStone, NMAkil, HGkika, TFischer, MDXue, KCehajic-Kapetanovic, JMacLaren, RECharbel Issa, PDownes, SMDe Silva, SRBackground: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Methods: Retrospective study at the Oxford Eye Hospital. Patients switched to faricimab from January to April 2023 with six months follow-up were identified via electronic medical records. Results: A total of 116 patients (151 eyes) were included. In 88 patients with nAMD (107 eyes), mean visual acuity remained stable: 62±17 ETDRS letters at baseline; 62±18 at six months (p > 0.05). Central subfield thickness (CST) reduced from 294 ± 73 μm to 270 ± 53 μm (p < 0.05) at six months. Subretinal or intraretinal fluid was present in 102 eyes (95%) at baseline and 75 eyes (70%) at follow-up (p < 0.05). Pigment epithelial detachment height decreased from 233 ± 134 μm to 188 ± 147 μm (p < 0.05). Mean treatment interval increased by 1.7 weeks (p < 0.05) and was extended in 61 eyes (57%) at six months. In 28 patients with DMO (44 eyes), visual acuity remained stable: 69 ± 15 letters at baseline; 70±15 at six months (p > 0.05). CST reduced from 355 ± 87 μm to 317 ± 82 μm (p < 0.05). Mean treatment interval increased by 1.4 weeks (p < 0.05) and was extended in 21 eyes (46%) by six months. Conclusions: Switching to faricimab in treatment resistant eyes led to improved anatomical response and extended treatment interval in a significant proportion of patients. Ongoing review of real-world data will inform longer-term outcomes of safety and effectiveness. |
| spellingShingle | Borchert, GA Kiire, CA Stone, NM Akil, H Gkika, T Fischer, MD Xue, K Cehajic-Kapetanovic, J MacLaren, RE Charbel Issa, P Downes, SM De Silva, SR Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema |
| title | Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema |
| title_full | Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema |
| title_fullStr | Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema |
| title_full_unstemmed | Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema |
| title_short | Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema |
| title_sort | real world six month outcomes in patients switched to faricimab following partial response to anti vegf therapy for neovascular age related macular degeneration and diabetic macular oedema |
| work_keys_str_mv | AT borchertga realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT kiireca realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT stonenm realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT akilh realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT gkikat realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT fischermd realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT xuek realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT cehajickapetanovicj realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT maclarenre realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT charbelissap realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT downessm realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema AT desilvasr realworldsixmonthoutcomesinpatientsswitchedtofaricimabfollowingpartialresponsetoantivegftherapyforneovascularagerelatedmaculardegenerationanddiabeticmacularoedema |